| scholarly article | Q13442814 |
| P50 | author | Margaret von Mehren | Q66809438 |
| R Katherine Alpaugh | Q88903151 | ||
| Hartmuth C. Kolb | Q15431265 | ||
| P2093 | author name string | Jian Q Yu | |
| Michael G Stabin | |||
| Joseph C Walsh | |||
| Mohan Doss | |||
| Vani P Mocharla | |||
| Eric D Hostetler | |||
| James B Stubbs | |||
| Marie-José Bélanger | |||
| James J Zhang | |||
| Michael Haka | |||
| P2860 | cites work | Dose to the Fetus from Radionuclides in the Bladder | Q69667012 |
| Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival | Q77162290 | ||
| Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer | Q77603503 | ||
| OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine | Q81816056 | ||
| Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels | Q29619679 | ||
| Biodistribution and radiation dosimetry of the hypoxia marker 18F–HX4 in monkeys and humans determined by using whole-body PET/CT | Q34471063 | ||
| Clinical biomarkers of angiogenesis inhibition | Q37139413 | ||
| Applications of click chemistry in radiopharmaceutical development. | Q42784387 | ||
| 18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies. | Q44240330 | ||
| [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates | Q44735126 | ||
| Biodistribution and radiation dosimetry of the A1 adenosine receptor ligand 18F-CPFPX determined from human whole-body PET. | Q46676993 | ||
| Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies | Q48615909 | ||
| SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. | Q52245161 | ||
| PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. | Q53540557 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 787-795 | |
| P577 | publication date | 2012-04-12 | |
| P1433 | published in | The Journal of Nuclear Medicine | Q7743608 |
| P1476 | title | Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans | |
| P478 | volume | 53 |
| Q36225629 | (18)F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases |
| Q34473605 | (68)Ga-PRGD2 PET/CT in the evaluation of Glioma: a prospective study |
| Q37624526 | (99m)Tc-Galacto-RGD2: a novel 99mTc-labeled cyclic RGD peptide dimer useful for tumor imaging. |
| Q33767056 | A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer |
| Q86837102 | A novel PET tracer for targeted imaging of atherosclerosis |
| Q85553370 | A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients |
| Q43821024 | A practical synthesis of [(18) F]FtRGD: an angiogenesis biomarker for PET. |
| Q30832796 | Application of (68)Ga-PRGD2 PET/CT for αvβ3-integrin imaging of myocardial infarction and stroke |
| Q35047646 | Atherosclerotic plaque uptake of a novel integrin tracer ¹⁸F-Flotegatide in a mouse model of atherosclerosis |
| Q53072001 | Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers. |
| Q48134659 | Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements |
| Q37540109 | Click Chemistry and Radiochemistry: The First 10 Years |
| Q26771417 | Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3 |
| Q38059503 | Clinical imaging of tumor angiogenesis. |
| Q55387769 | Comparison and evaluation of two RGD peptides labelled with 68Ga or 18F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma. |
| Q37705643 | Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects |
| Q61797301 | Diagnostic and Predictive Value of Using RGD PET/CT in Patients with Cancer: A Systematic Review and Meta-Analysis |
| Q39144300 | Efficient bioconjugation of 5-fluoro-5-deoxy-ribose (FDR) to RGD peptides for positron emission tomography (PET) imaging of α(v)β(3) integrin receptor. |
| Q51771438 | Evaluation of a Flexible NOTA-RGD Kit Solution Using Gallium-68 from Different 68Ge/68Ga-Generators: Pharmacokinetics and Biodistribution in Nonhuman Primates and Demonstration of Solitary Pulmonary Nodule Imaging in Humans. |
| Q36113183 | Evaluation of two novel ⁶⁴Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ₃. |
| Q41670915 | Exploring the Role of RGD-Recognizing Integrins in Cancer |
| Q49158345 | Feasibility of [18F]-RGD for ex vivo imaging of atherosclerosis in detection of αvβ3 integrin expression |
| Q33704623 | First in-human radiation dosimetry of 68Ga-NODAGA-RGDyK |
| Q34196969 | Impact of multiple negative charges on blood clearance and biodistribution characteristics of 99mTc-labeled dimeric cyclic RGD peptides |
| Q37236103 | Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics |
| Q58705363 | New transgenic NIS reporter rats for longitudinal tracking of fibrogenesis by high-resolution imaging |
| Q38228356 | PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. |
| Q37585965 | Peptide-based imaging agents for cancer detection |
| Q52984633 | RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study. |
| Q38166986 | RGD-based PET tracers for imaging receptor integrin αv β3 expression |
| Q39475901 | Radiation Dosimetry of a Novel Adenosine A2A Receptor Radioligand [11C]Preladenant Based on PET/CT Imaging and Ex Vivo Biodistribution in Rats |
| Q27321151 | Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide PET ligand [(18)F]-tetrafluoroborate |
| Q37358441 | Radiation dosimetry of the α4β2 nicotinic receptor ligand (+)-[18F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results. |
| Q89529826 | Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology |
| Q38342458 | Radiopharmaceuticals as probes to characterize tumour tissue |
| Q41766834 | Stereotactic Comparison Study of (18)F-Alfatide and (18)F-FDG PET Imaging in an LLC Tumor-Bearing C57BL/6 Mouse Model |
| Q37352633 | Suggested pathway to assess radiation safety of ¹⁸F-labeled PET tracers for first-in-human studies |
| Q50961964 | Synthesis of [18F]RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin αvβ3 expression in vivo. |
| Q49165125 | The Use of PET Imaging for Prognostic Integrin α2β1 Phenotyping to Detect Non-Small Cell Lung Cancer and Monitor Drug Resistance Responses |
| Q26849599 | The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals |
| Q44462472 | Using 5-deoxy-5-[18F]fluororibose to glycosylate peptides for positron emission tomography |
| Q31095114 | [(68)Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis |
Search more.